Intracoronary injection of drugs to treat no--reflow phenomenon and microcirculatory dysfunction

Area of Science:

• Cardiology
• Interventional Cardiology
• Vascular Biology

Background:

• ST-elevation myocardial infarction (STEMI) patients undergoing percutaneous coronary intervention (PCI) frequently experience incomplete myocardial reperfusion.
• The no-reflow phenomenon, characterized by reduced blood flow to infarct-related myocardium despite epicardial artery patency, occurs in 5-50% of STEMI cases.
• No-reflow is linked to adverse outcomes, including arrhythmias, heart failure, and increased 30-day mortality.

Purpose of the Study:

• To review current literature on the pathophysiology of the no-reflow phenomenon.
• To explore novel treatment strategies for no-reflow and microvascular dysfunction.
• To focus on the efficacy of intra-coronary drug injection for treating no-reflow.

Main Methods:

• Literature review of recent publications on no-reflow phenomenon.
• Analysis of studies investigating the pathophysiology of microvascular dysfunction in myocardial infarction.
• Evaluation of treatment strategies including vasodilators, mechanical devices, and antiplatelet agents.

Main Results:

• Percutaneous coronary intervention successfully restores epicardial artery flow but not always myocardial reperfusion.
• Prolonged ischemia can damage the coronary microvasculature, causing the no-reflow phenomenon.
• Emerging treatments aim to improve microvascular function and myocardial reperfusion.

Conclusions:

• The no-reflow phenomenon remains a significant challenge in STEMI management.
• Intra-coronary drug delivery is a promising therapeutic approach for no-reflow and microvascular dysfunction.
• Further research into targeted therapies is crucial for improving patient outcomes.